The Gelfand Clinical Research Lab designs and conducts clinic-based and population-based observational studies and interventional and translational clinical trials in common and rare skin diseases. Dr. Gelfand and his team focus on pharmacoepidemiology, patient centered outcomes and effectiveness research, psychometrics and instrument/diagnostic test development, and human translational studies aimed at the development of novel treatment approaches and further understanding of disease pathogenesis. A major goal of the Gelfand Clinical Research Program is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, cardiovascular disease and mortality.
Current research projects include: the Dermatology Clinical Effectiveness Research Network (DCERN), which collects data from dermatologists across the US to evaluate effectiveness of psoriasis treatments in real world settings; the Incident Health Outcomes and Psoriasis Events study (iHOPE), a study of 9000 psoriasis patients which evaluates how body surface area of skin involvement influences risk of cardiovascular disease; Vascular Inflammation in Psoriasis trials (VIP), which are multi-center trials that will determine the impact of psoriasis treatment on novel biomarkers of cardiometabolic disease; and the ASPIRE study, which investigates the effects of narrow-band ultraviolet B phototherapy on psoriatic plaques.
Check out our most recent publication!
The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study
Alexis Ogdie, Lauren Harter, Daniel Shin, Joshua Baker, Junko Takeshita, Hyon K Choi, Thorvardur Jon Love, Joel M Gelfand.